151 related articles for article (PubMed ID: 35876461)
1. Glycosphingolipid Changes in Plasma in Parkinson's Disease Independent of Glucosylceramide Levels.
Te Vruchte D; Sturchio A; Priestman DA; Tsitsi P; Hertz E; Andréasson M; Markaki I; Wallom KL; Platt F; Svenningsson P
Mov Disord; 2022 Oct; 37(10):2129-2134. PubMed ID: 35876461
[TBL] [Abstract][Full Text] [Related]
2. A Biomarker Study in Patients with GBA1-Parkinson's Disease and Healthy Controls.
den Heijer JM; Cullen VC; Pereira DR; Yavuz Y; de Kam ML; Grievink HW; Moerland M; Leymarie N; Khatri K; Sollomoni I; Spitalny L; Dungeon L; Hilt DC; Justman C; Lansbury P; Groeneveld GJ
Mov Disord; 2023 May; 38(5):783-795. PubMed ID: 36916660
[TBL] [Abstract][Full Text] [Related]
3. Glycosphingolipid levels and glucocerebrosidase activity are altered in normal aging of the mouse brain.
Hallett PJ; Huebecker M; Brekk OR; Moloney EB; Rocha EM; Priestman DA; Platt FM; Isacson O
Neurobiol Aging; 2018 Jul; 67():189-200. PubMed ID: 29735433
[TBL] [Abstract][Full Text] [Related]
4. A Phase 1B Trial in GBA1-Associated Parkinson's Disease of BIA-28-6156, a Glucocerebrosidase Activator.
den Heijer JM; Kruithof AC; Moerland M; Walker M; Dudgeon L; Justman C; Solomini I; Splitalny L; Leymarie N; Khatri K; Cullen VC; Hilt DC; Groeneveld GJ; Lansbury P
Mov Disord; 2023 Jul; 38(7):1197-1208. PubMed ID: 37195859
[TBL] [Abstract][Full Text] [Related]
5. Analysis of neutral glycosphingolipids from Trypanosoma brucei.
Uemura A; Watarai S; Kushi Y; Kasama T; Ohnishi Y; Kodama H
Vet Parasitol; 2006 Sep; 140(3-4):264-72. PubMed ID: 16806714
[TBL] [Abstract][Full Text] [Related]
6. High Glucosylceramides and Low Anandamide Contribute to Sensory Loss and Pain in Parkinson's Disease.
Klatt-Schreiner K; Valek L; Kang JS; Khlebtovsky A; Trautmann S; Hahnefeld L; Schreiber Y; Gurke R; Thomas D; Wilken-Schmitz A; Wicker S; Auburger G; Geisslinger G; Lötsch J; Pfeilschifter W; Djaldetti R; Tegeder I
Mov Disord; 2020 Oct; 35(10):1822-1833. PubMed ID: 32652698
[TBL] [Abstract][Full Text] [Related]
7. Plasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson's Disease.
Surface M; Balwani M; Waters C; Haimovich A; Gan-Or Z; Marder KS; Hsieh T; Song L; Padmanabhan S; Hsieh F; Merchant KM; Alcalay RN
Mov Disord; 2022 Feb; 37(2):416-421. PubMed ID: 34741486
[TBL] [Abstract][Full Text] [Related]
8. Mass spectrometric quantification of plasma glycosphingolipids in human GM3 ganglioside deficiency.
Aoki K; Heaps AD; Strauss KA; Tiemeyer M
Clin Mass Spectrom; 2019 Nov; 14 Pt B():106-114. PubMed ID: 34917767
[TBL] [Abstract][Full Text] [Related]
9. Evolution of prodromal parkinsonian features in a cohort of
Avenali M; Toffoli M; Mullin S; McNeil A; Hughes DA; Mehta A; Blandini F; Schapira AHV
J Neurol Neurosurg Psychiatry; 2019 Oct; 90(10):1091-1097. PubMed ID: 31221723
[TBL] [Abstract][Full Text] [Related]
10. A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy.
Cosden M; Jinn S; Yao L; Gretzula CA; Kandebo M; Toolan D; Hatcher NG; Ma L; Lemaire W; Adam GC; Burlein C; Minnick C; Flick R; Watt ML; Mulhearn J; Fraley M; Drolet RE; Marcus JN; Smith SM
Neurobiol Dis; 2021 Nov; 159():105507. PubMed ID: 34509608
[TBL] [Abstract][Full Text] [Related]
11. Sphingosine-1-Phosphate, Motor Severity, and Progression in Parkinson's Disease (MARK-PD).
Schwedhelm E; Englisch C; Niemann L; Lezius S; von Lucadou M; Marmann K; Böger R; Peine S; Daum G; Gerloff C; Choe CU
Mov Disord; 2021 Sep; 36(9):2178-2182. PubMed ID: 34008894
[TBL] [Abstract][Full Text] [Related]
12. Reversible Conformational Conversion of α-Synuclein into Toxic Assemblies by Glucosylceramide.
Zunke F; Moise AC; Belur NR; Gelyana E; Stojkovska I; Dzaferbegovic H; Toker NJ; Jeon S; Fredriksen K; Mazzulli JR
Neuron; 2018 Jan; 97(1):92-107.e10. PubMed ID: 29290548
[TBL] [Abstract][Full Text] [Related]
13. Glucosylceramide synthase and glycosphingolipid synthesis.
Ichikawa S; Hirabayashi Y
Trends Cell Biol; 1998 May; 8(5):198-202. PubMed ID: 9695839
[TBL] [Abstract][Full Text] [Related]
14. Glycosphingolipid metabolism and its role in ageing and Parkinson's disease.
Wallom KL; Fernández-Suárez ME; Priestman DA; Te Vruchte D; Huebecker M; Hallett PJ; Isacson O; Platt FM
Glycoconj J; 2022 Feb; 39(1):39-53. PubMed ID: 34757540
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal Fluid Profiles in Parkinson's Disease: No Accumulation of Glucosylceramide, but Significant Downregulation of Active Complement C5 Fragment.
Niimi Y; Mizutani Y; Akiyama H; Watanabe H; Shiroki R; Hirabayashi Y; Hoshinaga K; Mutoh T
J Parkinsons Dis; 2021; 11(1):221-232. PubMed ID: 33216044
[TBL] [Abstract][Full Text] [Related]
16. Putaminal y-Aminobutyric Acid Modulates Motor Response to Dopaminergic Therapy in Parkinson's Disease.
Seger AD; Farrher E; Doppler CEJ; Gogishvili A; Worthoff WA; Filss CP; Barbe MT; Holtbernd F; Shah NJ; Fink GR; Sommerauer M
Mov Disord; 2021 Sep; 36(9):2187-2192. PubMed ID: 34096652
[TBL] [Abstract][Full Text] [Related]
17. Glycosphingolipid accumulation in the aortic wall is another feature of human atherosclerosis.
Mukhin DN; Chao FF; Kruth HS
Arterioscler Thromb Vasc Biol; 1995 Oct; 15(10):1607-15. PubMed ID: 7583534
[TBL] [Abstract][Full Text] [Related]
18. A Large-Scale Full GBA1 Gene Screening in Parkinson's Disease in the Netherlands.
den Heijer JM; Cullen VC; Quadri M; Schmitz A; Hilt DC; Lansbury P; Berendse HW; van de Berg WDJ; de Bie RMA; Boertien JM; Boon AJW; Contarino MF; van Hilten JJ; Hoff JI; van Mierlo T; Munts AG; van der Plas AA; Ponsen MM; Baas F; Majoor-Krakauer D; Bonifati V; van Laar T; Groeneveld GJ
Mov Disord; 2020 Sep; 35(9):1667-1674. PubMed ID: 32618053
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal Fluid Levels of Kininogen-1 Indicate Early Cognitive Impairment in Parkinson's Disease.
Markaki I; Bergström S; Tsitsi P; Remnestål J; Månberg A; Hertz E; Paslawski W; Sorjonen K; Uhlén M; Mangone G; Carvalho S; Rascol O; Meissner WG; Magnin E; Wüllner U; Corvol JC; Nilsson P; Svenningsson P
Mov Disord; 2020 Nov; 35(11):2101-2106. PubMed ID: 33179332
[TBL] [Abstract][Full Text] [Related]
20. Features of
Malek N; Weil RS; Bresner C; Lawton MA; Grosset KA; Tan M; Bajaj N; Barker RA; Burn DJ; Foltynie T; Hardy J; Wood NW; Ben-Shlomo Y; Williams NW; Grosset DG; Morris HR;
J Neurol Neurosurg Psychiatry; 2018 Jul; 89(7):702-709. PubMed ID: 29378790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
